Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Inclusion Criteria: * Age \>18 years of age; male or female. * Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma. * Capable of providing informed consent and complying with trial procedures. * Karnofsky Performance Status (KPS) of \>/=70%. * Life expectancy \>/=12 weeks. * Measurable tumor lesions according to RECIST 1.1 criteria. * Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. Both male and female patients of reproductive potential must agree to use a reliable method of birth control during the study. Exclusion Criteria: * Patients must have received no previous radiotherapy, surgery, chemotherapy or investigational therapy for the treatment of metastatic disease. Prior treatments in the adjuvant setting with gemcitabine and/or 5-FU or gemcitabine administered as a radiation sensitizer are allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present. * Palliative surgery and/or radiation treatment less than 4 weeks prior to initiation of study treatment. * Exposure to any investigational agent within 4 weeks prior to initiation of study treatment. * Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit). * History of other malignancies (except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix) unless documented free of cancer for \>/= 5 years. * Laboratory values: Screening serum creatinine \> upper limits of normal (ULN); total bilirubin \> ULN: alanine aminotransferase (ALT) and AST \>/= 2.5 ULN or \>/= 5.0 x ULN if liver metastases are present; absolute neutrophil count \< 1,500/mm3, platelet concentration \< 100,00/mm3, hematocrit level \< 27% for females or \< 30% for males, or coagulation tests (prothrombin time \[PT\], partial thromboplastin time \[PTT\], International Normalized Ratio \[INR\]) \> 1.5 x ULN unless on therapeutic doses of warfarin. * current, serious, clinically significant cardiac arrhythmias as determined by the Investigator. * History of HIV infection. * Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals. * Major surgery within 4 weeks prior to initiation of study treatment. Any condition that might interfere with the patient's participation in the study or in the evaluation of the study results. * Any condition that is unstable and could jeopardize the patient's participation in the study.